The purpose of the study is to find out whether treatment with zanubrutinib for twelve months can lead to improvement in nerve function as measured by various scales that assess strength, sensation, and ability to perform daily activities. These scales help doctors understand how well patients can move, feel sensations, and carry out everyday tasks. The study will measure whether patients improve by at least one point on at least two of these measurement scales after one year of treatment.

During the study, patients will take zanubrutinib capsules daily for up to forty-eight months. The maximum daily amount is three hundred twenty milligrams, and the maximum total amount in a day is four hundred eighty milligrams. Doctors will regularly check nerve function using the measurement scales and will also perform nerve conduction studies, which are tests that measure how well electrical signals travel through the nerves. Blood tests will be done to measure the levels of abnormal proteins and anti-MAG antibodies at twelve, twenty-four, and forty-eight months to see if the treatment is reducing these harmful substances in the blood.

The purpose of this study is to determine how well these two medications work together in treating patients with relapsed or refractory MZL. Participants in the study will receive both medications over a period of up to 24 months. The study will monitor how the cancer responds to the treatment and will also keep track of any side effects experienced by the participants. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their treatment. The study aims to provide valuable information on whether the combination of acalabrutinib and tafasitamab can be an effective treatment option for patients with MZL who have limited options due to the return or resistance of their disease. This research could potentially lead to new treatment strategies for managing this type of lymphoma.

The study will test a medication called capivasertib (also known as TRUQAP) that comes in the form of film-coated tablets taken by mouth. Patients will receive either 160 mg or 200 mg tablets. This medication works by targeting specific processes that cancer cells use to grow and survive.

The main purpose of this study is to determine how well capivasertib works in treating these types of lymphoma by measuring how many patients show improvement after taking the medication. During the study, doctors will monitor patients’ responses to treatment through various medical examinations and imaging tests. They will also track how long any positive responses to the treatment last and evaluate the medication’s safety.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The purpose of this research is to evaluate how well obinutuzumab works and what side effects it may cause when used as a first treatment for people with MZL who cannot receive local treatments or for whom local treatments have not worked. The medication will be given as a single treatment, meaning it will not be combined with other cancer medications.

During the study, participants will receive obinutuzumab through an intravenous infusion at a dose of 1,000 mg. The treatment period may last up to 30 months. Throughout the study, doctors will monitor the participants’ response to treatment and track any side effects that may occur. The study will also look at how the treatment affects participants’ quality of life and whether any other health conditions develop over time.

The purpose of this study is to evaluate how safe and effective this new treatment is for patients whose cancer has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of MB-CART19.1 to use. In the second phase, they will assess how well the treatment works in reducing cancer cells in the body. Throughout the study, participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Participants will receive the MB-CART19.1 treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to find out if this approach can help control or eliminate the cancer, and how long any positive effects might last. The trial will also look at the overall health and survival of participants over time. Some participants may receive a placebo as part of the study to help compare the effects of the treatment. The study is expected to continue until the end of 2025.

The trial will investigate a new medication called Golcadomide (also known by its code name CC-99282), which is taken orally in capsule form. This medication will be tested both on its own and in combination with other treatments for NHL, including Rituximab, Obinutuzumab, Tafasitamab, and Valemetostat Tosylate. Rituximab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. The purpose of the study is to determine the safety and tolerability of Golcadomide alone and in combination with these other treatments, as well as to find the best dose to use in future studies.

Participants in the study will receive the medication and be monitored for any side effects or changes in their condition. The study will also look at how the body processes the medication and its preliminary effectiveness in treating the disease. The trial is designed to gather important information that could lead to new treatment options for people with relapsed or refractory NHL.

The purpose of the study is to evaluate how well Odronextamab works in shrinking tumors and to assess its safety in patients. The study includes several subtypes of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on how the cancer responds to Odronextamab and any changes in the patients’ health. This information will help determine the effectiveness of the treatment and its potential as a new option for patients with B-cell non-Hodgkin lymphoma. The study aims to provide valuable insights into the treatment of this type of cancer and improve future care for patients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of the study is to evaluate how effective and safe JCAR017 is for patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an injection into a vein. The study will follow the participants over a period to observe how their cancer responds to the treatment and to monitor any side effects they may experience. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects of the actual treatment.

Throughout the study, various assessments will be conducted to measure the response of the cancer to the treatment, including imaging tests like PET-CT or CT scans. The study will also look at how long the treatment effects last, the overall survival of participants, and any changes in their quality of life. The safety of the treatment will be closely monitored to ensure the well-being of all participants. This study aims to provide valuable information on the potential benefits and risks of using JCAR017 for treating these types of lymphoma.

Participants in the study will receive the treatment over a period of time, with ibrutinib being taken daily and rituximab administered at specific intervals. The study will monitor the participants’ response to the treatment, looking at how well the cancer responds and any side effects that may occur. The trial will also explore the treatment’s effects on different subtypes of marginal zone lymphoma, including extranodal marginal zone lymphoma (EMZL), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL).

The study aims to gather information on the complete response rate, which is the percentage of patients whose cancer disappears after treatment, and the progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse. Safety and overall survival will also be assessed. This information will help determine the potential benefits and risks of using ibrutinib and rituximab together for treating marginal zone lymphoma.

The purpose of the study is to determine which combination works better in treating these types of lymphomas. Participants will be randomly assigned to one of the two treatment groups. The study will begin with a phase to ensure the safety and tolerability of the odronextamab and lenalidomide combination. Following this, the main phase will compare the two treatment combinations to see which is more effective in preventing the cancer from getting worse. This will be assessed by looking at how long participants live without their disease progressing, known as progression-free survival.

Throughout the study, participants will receive their assigned treatments and will be monitored regularly to assess the effects of the treatments and any side effects. The study is expected to last for several years, allowing researchers to gather enough information to make a clear comparison between the two treatment options. This research is important for finding better ways to treat follicular lymphoma and marginal zone lymphoma, potentially improving outcomes for patients with these conditions.

Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor the participants over a period of time to see how their cancer responds to the treatment. This includes checking the levels of the modified immune cells in the blood and observing any changes in the cancer. The study will also look at the safety of the treatment by tracking any side effects that participants may experience.

In addition to Axicabtagene Ciloleucel, the study may involve other medications to support the treatment process. These include Tocilizumab, Dexamethasone, Fludarabine, Cyclophosphamide, Methylprednisolone, Diphenhydramine, Mesna, and Paracetamol. Some of these medications help manage side effects or enhance the effectiveness of the main treatment. The study aims to provide valuable information on how well this new treatment works and its potential benefits for patients with these types of lymphoma.

The purpose of the study is to determine if the [68Ga]Ga-PentixaFor imaging method is better at detecting cancerous lesions compared to the [18F]FDG method. Participants in the study will undergo both types of scans, and the results will be compared to see which method provides more accurate information about the presence and extent of the lymphoma. This comparison will help doctors understand which imaging technique is more effective for staging MZL and potentially other similar types of lymphomas.

Throughout the study, participants will receive the imaging agents through an intravenous injection, which means the substance is injected directly into a vein. The study will also assess the safety and tolerability of these imaging agents to ensure they are safe for use in patients. By participating in this trial, researchers hope to improve the way MZL is diagnosed and staged, ultimately leading to better treatment planning and management for patients with this condition.

The purpose of the study is to see if adding tafasitamab to the treatment makes it more effective for patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive either the combination of tafasitamab, lenalidomide, and rituximab or a combination of lenalidomide and rituximab, along with a placebo. The study will monitor the participants over a period to see how well the cancer responds to the treatment and to check for any side effects.

Throughout the study, participants will receive the medications through different methods. Tafasitamab and rituximab are given as an infusion, which means they are delivered directly into the bloodstream through a vein. Lenalidomide is taken orally in the form of capsules. The study aims to provide valuable information on whether the addition of tafasitamab can improve treatment outcomes for patients with these types of lymphoma.

The purpose of the study is to see how well these treatments work in controlling the cancer. Participants will be randomly assigned to receive one of the treatment combinations. Some participants will receive zanubrutinib with obinutuzumab, while others will receive lenalidomide with rituximab. The study will also look at how long the treatments can keep the cancer from getting worse and how they affect the overall health and quality of life of the participants. The study will take place over several months, with regular check-ups and assessments to monitor the participants’ health and the progress of the treatment.

Throughout the study, participants will undergo various tests, including imaging tests like MRI or CT scans, to measure the size of the cancer and see how it responds to the treatment. The study aims to provide valuable information on which treatment combination is more effective for patients with relapsed or refractory follicular or marginal zone lymphoma. This information could help improve future treatment options for these types of cancer.